FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892351730> ?p ?o ?g. }

• W2892351730 endingPage "33359" @default.
• W2892351730 startingPage "33348" @default.
• W2892351730 abstract "// Khalid N. Al-Zahrani 1, 2 , David P. Cook 1, 2 , Barbara C. Vanderhyden 1, 2 and Luc A. Sabourin 1, 2 1 Ottawa Hospital Research Institute, Centre for Cancer Therapeutics, Ottawa, Ontario, Canada 2 Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada Correspondence to: Luc A. Sabourin, email: lsabourin@ohri.ca Keywords: androgen receptor; Sox10; bioinformatics; biomarkers; breast cancer Received: April 10, 2018      Accepted: August 13, 2018      Published: September 07, 2018 ABSTRACT The Androgen Receptor (AR) has recently garnered a lot of attention as a potential biomarker and therapeutic target in hormone-dependent cancers, including breast cancer. However, several inconsistencies exist within the literature as to which subtypes of breast cancer express AR or whether it can be used to define its own unique subtype. Here, we analyze 1246 invasive breast cancer samples from the Cancer Genome Atlas and show that human breast cancers that have been subtyped based on their HER2, ESR1, or PGR expression contain four clusters of genes that are differentially expressed across all subtypes. We demonstrate that Sox10 is highly expressed in approximately one-third of all HER2/ESR1/PGR-low tumors and is a candidate biomarker of the triple-negative subtype. Although AR expression is acquired in many breast cancer cases, its expression could not define a unique subtype. Despite several reports stating that AR expression is acquired in HER2/ESR1/PGR triple-negative cancers, here we show that a low percentage of these cancers express AR (~20%). In contrast, AR is highly expressed in HER2-positive or ESR1/PGR-positive cancers (> 95%). Although AR expression cannot be used as an independent subtype biomarker, our analysis shows that routine evaluation of AR expression in tumors which express HER2, ESR1 and/or PGR may identify a unique subset of tumors which would benefit from anti-androgen based therapies." @default.
• W2892351730 created "2018-09-27" @default.
• W2892351730 creator A5026081262 @default.
• W2892351730 creator A5039075996 @default.
• W2892351730 creator A5081090045 @default.
• W2892351730 creator A5086982868 @default.
• W2892351730 date "2018-09-07" @default.
• W2892351730 modified "2023-10-17" @default.
• W2892351730 title "Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling" @default.
• W2892351730 cites W165591743 @default.
• W2892351730 cites W1851611944 @default.
• W2892351730 cites W1924942058 @default.
• W2892351730 cites W1974738527 @default.
• W2892351730 cites W1978173438 @default.
• W2892351730 cites W1982093899 @default.
• W2892351730 cites W2017409068 @default.
• W2892351730 cites W2018020283 @default.
• W2892351730 cites W2025784247 @default.
• W2892351730 cites W2027586930 @default.
• W2892351730 cites W2031502665 @default.
• W2892351730 cites W2035077913 @default.
• W2892351730 cites W2044702943 @default.
• W2892351730 cites W2046885420 @default.
• W2892351730 cites W2048375037 @default.
• W2892351730 cites W2049420719 @default.
• W2892351730 cites W2066020368 @default.
• W2892351730 cites W2066985179 @default.
• W2892351730 cites W2068326991 @default.
• W2892351730 cites W2084625379 @default.
• W2892351730 cites W2092618961 @default.
• W2892351730 cites W2095249856 @default.
• W2892351730 cites W2095933146 @default.
• W2892351730 cites W2096283457 @default.
• W2892351730 cites W2097255042 @default.
• W2892351730 cites W2109386956 @default.
• W2892351730 cites W2112687290 @default.
• W2892351730 cites W2116760308 @default.
• W2892351730 cites W2123950418 @default.
• W2892351730 cites W2127057139 @default.
• W2892351730 cites W2131994307 @default.
• W2892351730 cites W2132893003 @default.
• W2892351730 cites W2136879321 @default.
• W2892351730 cites W2143336748 @default.
• W2892351730 cites W2157285286 @default.
• W2892351730 cites W2157375575 @default.
• W2892351730 cites W2165125351 @default.
• W2892351730 cites W2259802687 @default.
• W2892351730 cites W2288763477 @default.
• W2892351730 cites W2316437103 @default.
• W2892351730 cites W2332315774 @default.
• W2892351730 cites W2381569410 @default.
• W2892351730 cites W2530991050 @default.
• W2892351730 cites W2560367415 @default.
• W2892351730 cites W2606715885 @default.
• W2892351730 cites W2783620485 @default.
• W2892351730 cites W2795867722 @default.
• W2892351730 cites W2517022125 @default.
• W2892351730 doi "https://doi.org/10.18632/oncotarget.26072" @default.
• W2892351730 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6161783" @default.
• W2892351730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30279965" @default.
• W2892351730 hasPublicationYear "2018" @default.
• W2892351730 type Work @default.
• W2892351730 sameAs 2892351730 @default.
• W2892351730 citedByCount "13" @default.
• W2892351730 countsByYear W28923517302018 @default.
• W2892351730 countsByYear W28923517302019 @default.
• W2892351730 countsByYear W28923517302020 @default.
• W2892351730 countsByYear W28923517302021 @default.
• W2892351730 countsByYear W28923517302022 @default.
• W2892351730 countsByYear W28923517302023 @default.
• W2892351730 crossrefType "journal-article" @default.
• W2892351730 hasAuthorship W2892351730A5026081262 @default.
• W2892351730 hasAuthorship W2892351730A5039075996 @default.
• W2892351730 hasAuthorship W2892351730A5081090045 @default.
• W2892351730 hasAuthorship W2892351730A5086982868 @default.
• W2892351730 hasBestOaLocation W28923517301 @default.
• W2892351730 hasConcept C121608353 @default.
• W2892351730 hasConcept C126322002 @default.
• W2892351730 hasConcept C143998085 @default.
• W2892351730 hasConcept C2780110267 @default.
• W2892351730 hasConcept C2780192828 @default.
• W2892351730 hasConcept C2781197716 @default.
• W2892351730 hasConcept C502942594 @default.
• W2892351730 hasConcept C530470458 @default.
• W2892351730 hasConcept C54355233 @default.
• W2892351730 hasConcept C61367390 @default.
• W2892351730 hasConcept C71924100 @default.
• W2892351730 hasConcept C86803240 @default.
• W2892351730 hasConceptScore W2892351730C121608353 @default.
• W2892351730 hasConceptScore W2892351730C126322002 @default.
• W2892351730 hasConceptScore W2892351730C143998085 @default.
• W2892351730 hasConceptScore W2892351730C2780110267 @default.
• W2892351730 hasConceptScore W2892351730C2780192828 @default.
• W2892351730 hasConceptScore W2892351730C2781197716 @default.
• W2892351730 hasConceptScore W2892351730C502942594 @default.
• W2892351730 hasConceptScore W2892351730C530470458 @default.
• W2892351730 hasConceptScore W2892351730C54355233 @default.
• W2892351730 hasConceptScore W2892351730C61367390 @default.

• next